The state of Michigan currently has 406 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
NCT05053152
Recruiting
This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan +16 locations
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan +43 locations
Conditions: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040
Recruiting
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Register for Updates
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
NCT04681131
Recruiting
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: University of Michigan Comprehensive Cancer Center, Detroit, Michigan
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
NCT05526079
Recruiting
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/26/2024
Locations: Ascension St. John Hospital, Detroit, Michigan
Conditions: Rectal Cancer
Register for Updates
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
NCT05583422
Recruiting
This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results. Standard of care treatment will be initiated with either Fluoropyrimidine or Irinotecan therapy. Retrospective collection of treatment related AEs and SAEs, dose delays, dose reductions, and treatment discontinuations will be completed.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Cancer
Register for Updates
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
NCT06234748
Recruiting
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3. The study team aims to determine if it is feasible to use multi-modality imaging (both DCE MRI and FDG-PET) to optimize the radiation boost in high risk p16+ OPSCC with similar or decreased toxicity compared to historic standard therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Oropharynx Cancer, HPV-Related Carcinoma
Register for Updates
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT05183126
Recruiting
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer
Register for Updates
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
NCT03099356
Recruiting
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Cancer Center, Ann Arbor, Michigan
Conditions: Metastatic Thyroid Cancer
Register for Updates
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631744
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.
Gender:
Male
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Prostate Cancer
Register for Updates
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT04703920
Recruiting
This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
Register for Updates
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
NCT05038332
Recruiting
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy [SBRT]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Prostate Cancer
Register for Updates